loading
Atai Life Sciences N V stock is traded at $2.205, with a volume of 621.92K. It is up +0.43% in the last 24 hours and up +7.26% over the past month. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
See More
Previous Close:
$2.20
Open:
$2.2
24h Volume:
621.92K
Relative Volume:
0.31
Market Cap:
$474.18M
Revenue:
$314.00K
Net Income/Loss:
$-40.23M
P/E Ratio:
-7.875
EPS:
-0.28
Net Cash Flow:
$-84.71M
1W Performance:
-5.17%
1M Performance:
+7.26%
6M Performance:
+76.76%
1Y Performance:
+69.96%
1-Day Range:
Value
$2.1747
$2.24
1-Week Range:
Value
$2.00
$2.51
52-Week Range:
Value
$1.03
$2.64

Atai Life Sciences N V Stock (ATAI) Company Profile

Name
Name
Atai Life Sciences N V
Name
Phone
49 89 2153 9035
Name
Address
WALLSTRASSE 16, BERLIN
Name
Employee
54
Name
Twitter
Name
Next Earnings Date
2024-12-11
Name
Latest SEC Filings
Name
ATAI's Discussions on Twitter

Compare ATAI with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ATAI
Atai Life Sciences N V
2.205 474.18M 314.00K -40.23M -84.71M -0.28
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.52 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
519.49 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
316.61 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
558.49 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
257.51 28.51B 3.81B -644.79M -669.77M -6.24

Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-18-24 Reiterated H.C. Wainwright Buy
Apr-03-24 Upgrade Maxim Group Hold → Buy
Nov-01-22 Initiated Loop Capital Buy
Nov-30-21 Initiated Maxim Group Buy
Nov-11-21 Initiated ROTH Capital Buy
Oct-18-21 Initiated H.C. Wainwright Buy
Sep-01-21 Initiated Jefferies Buy
Jul-13-21 Initiated Berenberg Buy
Jul-13-21 Initiated Canaccord Genuity Buy
Jul-13-21 Initiated Cantor Fitzgerald Buy
Jul-13-21 Initiated Citigroup Buy
Jul-13-21 Initiated Cowen Outperform
Jul-13-21 Initiated Credit Suisse Outperform
Jul-13-21 Initiated RBC Capital Mkts Sector Perform
Jul-08-21 Initiated Aegis Capital Buy
View All

Atai Life Sciences N V Stock (ATAI) Latest News

pulisher
Jun 18, 2025

ATAI Sees Potential Boost from U.S. Policy Shift on Psychedelics - GuruFocus

Jun 18, 2025
pulisher
Jun 15, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders - GlobeNewswire

Jun 15, 2025
pulisher
Jun 15, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders - GlobeNewswire Inc.

Jun 15, 2025
pulisher
Jun 13, 2025

ATAI’s Stock Dilemma: ATAI Life Sciences N.V’s Market Performance and Outlook - investchronicle.com

Jun 13, 2025
pulisher
Jun 13, 2025

SELLAS Life Sciences Group Inc (SLS) Stock: A Year of Highs and Lows - investchronicle.com

Jun 13, 2025
pulisher
Jun 12, 2025

Atai Life Sciences (ATAI) Garnered a Buy Rating and $12 Target | ATAI Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 09, 2025

Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great Choice - Yahoo Finance

Jun 09, 2025
pulisher
Jun 09, 2025

Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Jun 09, 2025
pulisher
Jun 07, 2025

Lucid Capital Markets initiates coverage on atai Life Sciences stock By Investing.com - Investing.com Nigeria

Jun 07, 2025
pulisher
Jun 06, 2025

ATAI Gains Buy Rating and Price Target from Lucid Capital | ATAI Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Lucid Capital Markets initiates coverage on atai Life Sciences stock - Investing.com

Jun 06, 2025
pulisher
Jun 05, 2025

ATAI and Beckley Psytech Set to Merge in Strategic All-Share Dea - GuruFocus

Jun 05, 2025
pulisher
Jun 04, 2025

Regeneron makes obesity push; Atai, Alto ink brain drug deals - Yahoo Finance

Jun 04, 2025
pulisher
Jun 03, 2025

Atai Life Sciences Merges With Beckley Psytech In Major Shakeup - Finimize

Jun 03, 2025
pulisher
Jun 03, 2025

ATAI Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Atai Life Sciences N.V. is Fair to Shareholders - Business Wire

Jun 03, 2025
pulisher
Jun 03, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, STRM, ATAI, STR on Behalf of Shareholders - Morningstar

Jun 03, 2025
pulisher
Jun 03, 2025

H.C. Wainwright maintains buy rating on atai Life Sciences stock By Investing.com - Investing.com India

Jun 03, 2025
pulisher
Jun 03, 2025

H.C. Wainwright maintains buy rating on atai Life Sciences stock - Investing.com

Jun 03, 2025
pulisher
Jun 03, 2025

Atai in $370M merger deal with psychedelic drug specialist Beckley - BioWorld MedTech

Jun 03, 2025
pulisher
Jun 02, 2025

atai Life Sciences (ATAI) Merges with Beckley Psytech for Psyche - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

atai Life Sciences and Beckley Psytech merging - Seeking Alpha

Jun 02, 2025
pulisher
Jun 02, 2025

Atai Life Sciences, Beckley Psytech to Merge in All-Stock Transaction - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Transcript : Atai Life Sciences N.V., Beckley Psytech LimitedM&A Call - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Thiel-Backed Psychedelic Drugmaker Atai to Combine With Beckley - Bloomberg

Jun 02, 2025
pulisher
Jun 02, 2025

ATAI and Beckley Psytech Plan Merger in Strategic All-Share Deal | ATAI Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies - Yahoo Finance

Jun 02, 2025
pulisher
Jun 02, 2025

ATAI Life Sciences stock soars on Beckley Psytech merger deal By Investing.com - Investing.com UK

Jun 02, 2025
pulisher
May 30, 2025

Beckley Psytech & atai Life Sciences to combine expertise in pivotal merger - Mugglehead Magazine

May 30, 2025
pulisher
May 29, 2025

atai Life Sciences to Participate in Upcoming Investor Conferences - Yahoo

May 29, 2025
pulisher
May 27, 2025

2 ‘Strong Buy’ Psychedelic Stocks To Scoop Up ASAP - Barchart.com

May 27, 2025
pulisher
May 24, 2025

Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors - Benzinga

May 24, 2025
pulisher
May 23, 2025

atai Life Sciences N.V. (ATAI) Is Up 18.71% in One Week: What You Should Know - Nasdaq

May 23, 2025
pulisher
May 22, 2025

atai Life Sciences N.V. (ATAI) Just Flashed Golden Cross Signal: Do You Buy? - sharewise

May 22, 2025
pulisher
May 22, 2025

Is atai Life Sciences (ATAI) Outperforming Other Medical Stocks This Year? - Yahoo Finance

May 22, 2025
pulisher
May 21, 2025

atai Life Sciences holds annual general meeting - Investing.com Australia

May 21, 2025
pulisher
May 21, 2025

atai Life Sciences holds annual general meeting By Investing.com - Investing.com India

May 21, 2025
pulisher
May 21, 2025

ATAI Life Sciences Approves Key Governance Changes - TipRanks

May 21, 2025
pulisher
May 21, 2025

Phase 2a data for BPL-003 ‘encouraging’ for Atai Life Sciences, says Jefferies - Yahoo Finance

May 21, 2025
pulisher
May 21, 2025

ATAI Life Sciences Sees Significant Rise in Borrow Rate | ATAI S - GuruFocus

May 21, 2025

Atai Life Sciences N V Stock (ATAI) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Atai Life Sciences N V Stock (ATAI) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Kirpekar Sahil
Chief Business Officer
Mar 21 '25
Sale
1.35
48,563
65,560
115,636
Craig Kevin James
Chief Medical Officer
Mar 21 '25
Sale
1.35
11,563
15,610
8,437
Rao Srinivas
See Remarks
Mar 21 '25
Sale
1.35
75,418
101,814
212,942
Johnson Anne Nagengast
Chief Financial Officer
Mar 21 '25
Sale
1.35
33,545
45,286
140,045
Short Glenn Frank
Chief Scientific Officer
Mar 21 '25
Sale
1.35
13,161
17,767
42,333
$20.61
price up icon 0.78%
$36.03
price up icon 0.39%
$21.65
price up icon 1.34%
$105.24
price up icon 0.02%
$104.98
price up icon 0.19%
biotechnology ONC
$264.93
price down icon 1.26%
Cap:     |  Volume (24h):